

Is It Time to Revisit the Role of Interleukin-1 Inhibitors in Osteoarthritis?

Martin Brom¹, Franziska Saxer^{1,2}, Linda Mindeholm¹, Matthias Schieker¹, Philip G Conaghan³

¹Translational Medicine, Novartis Biomedical Research, Basel, Switzerland; ²Medical Faculty, University of Basel, Basel, Switzerland; ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, UK

Correspondence: Franziska Saxer, Email franziska.saxer@novartis.com

Objective: There remains a huge unmet need for new osteoarthritis (OA) therapies. A putative reason for the failure of some therapies has been the absence of well-defined phenotypes, which might be more appropriate for specific targeted treatment. Interleukin-1 (IL-1) plays a key role in the development of OA, but the results of clinical trials targeting IL-1 in OA have to date been disappointing.

Methods: This narrative review is based on a literature search for publications describing interventions with direct IL-1 pathway inhibitors in patients with knee OA and substantiated by a description of key pre-clinical observations.

Results: Randomized controlled studies using IL-1 inhibition as treatment approach to knee OA have read out negatively, although trends for an improvement in pain and impact on biomarkers could be observed. However, in a post-hoc analysis of the large CANTOS trial data (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) testing an anti-IL-1 monoclonal antibody for the secondary prevention of cardiovascular events treatment arms receiving canakinumab demonstrated a substantial reduction in the incidence rate of joint replacement compared to those receiving placebo. Similar results have been reported from a post-hoc analysis of another cardiovascular risk reduction study, the low-dose colchicine 2 (LoDoCo 2) trial, raising the possibility of a beneficial effect of IL-1 inhibition in the subset of patients with metabolic phenotype.

Conclusion: Based on the above results, it seems timely to revisit the role of IL-1 in OA, its relationship with chronic low-grade inflammation and its relevance in the subset of metabolic OA.

Keywords: cytokines, inflammation, disease modifying osteoarthritis drug, drug development, metabolic syndrome, low grade inflammation

Introduction

Osteoarthritis (OA) is the most common form of arthritis,¹ with a growing prevalence, and the 14th leading cause of age-standardized years lived with disability and 7th for people aged 70 and older.² It is a complex disease, with diverse underlying pathologic mechanisms, and with potentially several structural and pain phenotypes.^{3–9} Major risk factors for the development of OA are age, obesity, trauma, mechanical and genetic factors,^{10,11} Metabolic disbalance is considered a likely contributor to OA development, although its impact is not fully elucidated,¹² treatment primarily focusses on behavioral aspects and pain management, as there are no approved disease-modifying OA drugs (DMOADs), with joint replacement remaining as the last resort.¹³

Interleukin-1 (IL-1) is a crucial and highly controlled pro-inflammatory cytokine that plays a central role in the immune system as part of the defense mechanisms of the innate immune system, but with broad implications also on specific immunity. IL-1 secretion triggers an inflammatory cascade but also influences glucose metabolism.¹⁴ IL-1 also plays a key role in the pathogenesis of OA,^{15–20} accordingly, IL-1 inhibition has been considered a potential treatment strategy. Pre-clinical studies^{21–26} and a small case series²⁷ have suggested IL-1 inhibition to be effective but results from randomized clinical trials (RCTs) have been disappointing for knee OA.^{28–31} There are several possible reasons for this incongruity, including the types of pre-clinical models³² or patient selection in RCTs. Not all patients may benefit from IL-1 inhibition,

and it is possible that primarily people with local or systemic inflammation are the appropriate target.^{33–36} This hypothesis is supported by the post-hoc analyses of 2 trials for prevention of major cardiovascular events, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS),³⁷ evaluating the effect of IL-1 β inhibition, and the low-dose colchicine 2 (LoDoCo 2) trial,³⁸ investigating the effect of the non-specific inhibitor of the inflammasome, colchicine, which is critical for production of activated IL-1. The post-hoc analyses of both studies showed a significant reduction in the incidence of joint replacements in the treatment arms,^{39,40} prompting the reconsideration of the role of IL-1 inhibition in OA. We will therefore review the role of IL-1, critically examine the clinical trial experience and explore the implications of new study data.

Methods

This narrative review is based on a non-systematic search of current literature in PubMed[®] using the search terms “Interleukin 1”, “IL-1” and “knee osteoarthritis” in various combinations, using different notations and wildcards to identify reports on treatment approaches for knee OA with IL-1 inhibitors. In addition, reference lists from articles were screened. Only studies using direct IL-1 inhibitors were included, while studies that evaluate substances acting via an indirect effect on IL-1 (Chondroitin Sulfate, Glucosamine, Diacerein, Avocado and Soya extracts), microRNA, or autologous preparations were not taken into account. In addition, the literature was screened for publications on IL-1 in preclinical models of OA as well as the association of pain and IL-1.

Interleukin-1 in the Pathophysiology of Osteoarthritis

Interleukin-1 is produced by chondrocytes, mononuclear cells and macrophages, osteoblasts and synoviocytes in two isoforms, IL-1 α and IL-1 β .^{15,41} The IL-1 receptor, IL-1RI, is a transmembrane protein with an extracellular immunoglobulin-like receptor and a cytosolic TIR (Toll/interleukin-1 receptor/resistance protein) domain. Upon binding, IL-1RI recruits the co-receptor IL-1 Receptor Accessory Protein (IL-1RAP) and forms a heterodimeric receptor complex that activates the mitogen-activated protein kinase (MAPK) pathway, leading to activation of transcription factors NF- κ B and AP-1.^{19,20} This results in a shift towards a pro-inflammatory and catabolic state associated with a downregulation of synthesis of type II collagen and aggrecan, chondrocyte apoptosis and enhanced production of matrix degrading proteins, pro-inflammatory cytokines such as IL-6.^{15,42,43} In addition, extra cellular matrix (ECM) degradation products induce a positive feedback loop that further augments production of pro-inflammatory cytokines.⁴³ The activity of IL-1 is modulated by two endogenous antagonists, namely a decoy receptor IL-1RII, which has no cytoplasmic domain and the IL-1 receptor antagonist (IL-1-Ra), which binds to the IL-1RI without inducing a biologic response.^{20,44} A recent meta-analysis on IL-1 genetic polymorphisms identified variants that, in Caucasians especially 1RN*1/*1 and IL-1RN*1/*2 polymorphisms, were associated with an increased risk (OR, 0.50; 95% CI, 0.28–0.89; $I^2 = 84$, $p = 0.02$ and OR, 1.77; 95% CI 1.03–3.06, $I^2 = 86$, $p = 0.04$, respectively) for knee OA.⁴⁵

IL-1 affects various cell types such as osteoblasts, osteoclasts, synoviocytes and immune cells, ultimately perpetuating inflammation. This triggers the release of matrix degrading enzymes, leads to a reduction in matrix production, drives synovitis and alters the subchondral bone potentially impacting metabolic exchange at the bone cartilage interface.

Interleukin-1 in Osteoarthritis Pain

For people living with OA, pain is the most important symptom.^{5,7,46,47} IL-1 can induce pain by activating nociceptors through an intracellular kinase, enhancing the production of nitric oxide, kinins, and prostanoids such as prostaglandin E2.^{46,48,49} The latter exerts its effect by binding to a variety of E prostanoid receptors present in peripheral sensory neurons and the spinal cord.⁴⁶ IL-1 induced inflammation is also responsible for the induction of angiogenesis, with vessels that penetrate the calcified cartilage from subchondral bone, and whose perivascular sensory structures are believed to play a role in pain signaling.⁵⁰ Moreover, IL-1 can induce dysregulation of the autonomic nervous system, and consequently of the anti-inflammatory effect exerted by vagal reflex, and the circadian rhythm.⁵¹

IL-1 has also been implicated in changes in central pain processing (see [Supplemental Figure 1](#)). In the central nervous system, IL-1 is predominantly produced by microglia, astrocytes and specific neurons, and interacts with these cell types.⁵² Results from animal models suggest that in the spinal cord IL-1 associated long-term potentiation,⁵³

neuronal plasticity⁵⁴ and increase in cytokine secretion occur as mechanisms involved in central pain sensitization. Changes in IL-1 expression in association with neuropathic pain have also been observed in supraspinal areas that are typically involved in pain processing.^{55–57} Finally, IL-1 has been implicated in mood disturbances such as anxiety and depression⁵⁸ which associate with incident OA pain⁵⁹ and may increase the risk for chronic pain.⁶⁰

Attur et al reported that overexpression of IL-1 was significantly associated with higher pain levels (Western Ontario and McMaster Universities (WOMAC) pain subscale and Visual Analogue Score (VAS) pain) in OA patients even after adjusting for sex, age and body mass index (BMI).⁶¹

IL-1 Inhibition in Animal Models

In the 1990s, a recombinant human IL-1 receptor antagonist (RHuIL-1Ra) had a dose-dependent protective effect in vivo against both cartilage loss and osteophyte formation at 4 weeks in a canine OA model.²³ A subsequent study reported that intra-articular (IA) injection of autologous synoviocytes transduced to express IL-1Ra had a protective effect on cartilage after 4 weeks,²² an effect confirmed by others.^{24,25} In line with these protective effects related to IL-1 inhibition, reduction in OA severity has been observed in IL-1 β knockout mice⁶² and gene therapy approaches using IL-1Ra or IL-1RII have been successful preclinically in reducing both pain and structural damage.⁶³ The relevance of IL-1 for joint health may be multi-faceted though since accelerated development of OA in knockout mice for IL-1 β and IL-1 β converting enzyme has also been observed.⁶⁴ In contrast, no changes in synovial inflammation or in cartilage destruction were reported in IL-1 knockout mice with collagenase-induced OA.⁶⁵

Overall, the role of IL-1 in animal models is not fully clear and may depend on the pain stimulus, the species, the behavioral endpoint and the evaluated region in the central nervous system.⁶⁶ In addition, as Vincent has argued³² several types of bias may affect the interpretation of these preclinical results such as lack of animal randomization, lack of investigator blinding, a trend towards underpowered studies, and publication bias.

The Results of IL-1 Inhibition in Knee OA Clinical Trials

A recent systematic review by Yu et al identified 12 studies evaluating the effect of substances targeting IL-1 activity.⁶⁷ Herein, we examine the four studies (Table 1) in knee OA that evaluated specific targeting of the IL-1 pathway.^{28–31}

Anakinra (Recombinant IL-1Ra)

Chevalier et al published a case series piloting a single IA injection of anakinra for knee OA²⁷ in 14 patients followed for 12 weeks. This patient series demonstrated anakinra to be safe. Treatment was associated with significant improvement in the VAS pain and WOMAC for the whole study period. The group subsequently performed an RCT in 170²⁸ comparing a single IA dose of anakinra 50 mg or 150 mg to placebo. Anakinra was safe, and although WOMAC pain scores improved with anakinra 150 mg at Day 4 ($p = 0.051$), this effect was lost subsequently and the Week 4 primary endpoint was not met.

AMG108 Fully Human Monoclonal Antibody Against IL-1RI

The IL-1RI antibody AMG108 was studied in knee OA²⁹ using a two-part RCT: Part A evaluated dose-ranging, safety and pharmacokinetics in 58 patients, while Part B aimed to determine clinical efficacy in 160 patients, randomized 1:1 to receive placebo or AMG-108 300 mg sc. every 4 weeks for 12 weeks. AMG108 did not differ significantly from placebo in terms of the primary endpoint (change in WOMAC pain at Week 6), although numerical superiority for pain improvement and a reduction in need for rescue therapy were noted.

Canakinumab (Human Monoclonal Antibody to IL-1 β)

Conaghan et al performed a two-part study to evaluate safety and efficacy of a single IA treatment with canakinumab in painful knee OA.³¹ The first part was a double-dummy placebo-controlled, single ascending dose safety study, followed by an 18-week randomized placebo and naproxen-controlled trial, in which 136 patients were randomized to receive a single IA injection of canakinumab 600 mg or placebo at Baseline, and naproxen 500 mg twice daily or placebo until Week 12 in a double-blind, double-dummy design. The effect of canakinumab was not different from placebo or naproxen for the co-primary endpoints, change from Baseline to Day 4 in knee pain (VAS 0–100 mm) and change

Table 1 Comparison of Clinical Trials for IL-1 Inhibition in Knee OA

	Anakinra^a	AMG – 108 (part B)^b	Lutikizumab^c	Canakinumab^d
Mechanism of Action	Recombinant IL-1R antagonist	Anti-IL-1R MAb	DVD-Ig anti IL-1 α and -1 β	Anti-IL-1 β Mab
Half-life (Hours)	4	N/D	240–336	624
Route of administration	Single IA dose	SC every 4 weeks	SC every 2 weeks	Single IA dose
Primary endpoint	WOMAC at Week 4	WOMAC pain score at Week 6	WOMAC pain score at Week 16 Synovitis (MRI) at Week 26	VAS pain at Day 4 WOMAC pain score at Week 4
Secondary endpoint	WOMAC change/visit. WOMAC improvement >50% at W12 Pain VAS Global Activity VAS PGA by Likert Rescue analgesic use. PROs: HRPQ, EuroQol-5D, SF36 Cleavage products or pro-peptides of collagen synthesis Safety	Safety Pharmacokinetics WOMAC change Week 6 and 12. Change pain VAS Change SF36 Change EuroQol	WOMAC pain score at Week 26 and 52 OMERACT/OARSI response at Week 16, 26, and 52 Radiographic joint space narrowing at Week 52. Synovitis at Week 26 by dynamic contrast enhanced MRI	Change in Pain VAS and WOMAC subscales at every visit. Pain VAS improvement $\geq$ 50% Use of rescue medication Pharmacokinetics Pharmacodynamics
Follow-Up (months)	3	3	12	3
Control	Pbo	Pbo	Pbo	Pbo and NPX
Inclusion Criteria	Pts >18 years ACR criteria for knee OA Pain VAS > 30 mm KL 1–3	Pts >30 years ACR criteria for knee OA Pain VAS > 30 mm KL 1–3	Pts > 35 <74 years Pain VAS >40 <80 Global VAS $\geq$ 40 KL 2–3 in the medial compartment Synovitis (US or MRI)	Pts >40 <80 years ACR criteria for knee OA Pain VAS $\geq$ 40 KL 2–3 BMI $\leq$ 45
Pts included	AKN 150 mg: 67 AKN 50 mg: 34 Pbo: 69	AMG-108 300 mg SC: 80 Pbo: 79	LTZ 25 mg: 89 LTZ 100 mg: 85 LTZ 200 mg: 88 Pbo: 85	CKN 600 mg: 45 NPX 500 mg BID: 53 Pbo: 47
Age (mean)	63	60	60	61.3
Female (%)	65	68	64.9	76.2
BMI	N/D	32	29	31.4
OA duration (y)	6.1	6.1	8	N/D

(Continued)

Table 1 (Continued).

	Anakinra^a	AMG – 108 (part B)^b	Lutikizumab^c	Canakinumab^d
KL 1 (%)	0	AMG-108: 1 Pbo: 5	0	0
KL 2 (%)	40	AMG-108: 50 Pbo: 38	63	53.1
KL 3 (%)	58	AMG-108: 49 Pbo: 58	37	46.9
KL 4 (%)	2	0	0	0
Synovitis (%)	0	N/D	100	N/D
Mean VAS of Pain (0–100 mm)	51.9	N/D	N/D	CKN 62.2 NPX 57.1 PBO 59.8
WOMAC's Pain Scale (mean)	AKN 25.7 PBO 25.8	AMG-108 27.9 PBO 26.8	LTZ 27.5 Pbo 26.2	10.2
Concomitant medication	Slow Acting Drugs Opioids Orthotic support	Slow acting drugs Orthotic support	Not allowed before Week 26	Stable doses of Opioids
Conclusion	Primary EP not met. No improvement in knee pain, function, stiffness, or cartilage turnover No safety concerns. Trend toward pain reduction on Day 4	Non-significant but numerically greater improvement in WOMAC pain score at W6 in the AMG-108 group, especially in those with higher score at Baseline	Only LTZ 100 mg achieved significant WOMAC reduction at Week 16 and was not sustained. Structural endpoints similar between LTZ and Pbo No safety concerns	No significant difference in outcomes Patients on PBO required more rescue medication. Significant improvement in WOMAC pain at Week 12 in the subgroup of high hsCRP patients.

Notes: ^a Chevalier X et al. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum.* 2009 Mar 15;61(3):344–52. ^b Cohen et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1RI) in patients with osteoarthritis of the knee. *Arthritis Res Ther.* 2011;13(4):R125. ^c Fleischmann RM et al. A Phase II Trial of Lutikizumab, an Anti-Interleukin-1 α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. *Arthritis Rheumatol.* 2019 Jul 7;71(7):1056–69. ^d Conaghan P et al. Intraarticular Canakinumab (Anti-Interleukin-1 β) for treatment of symptomatic knee osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II study [abstract]. *Arthritis Rheumatol.* 2021;73(suppl9).

Abbreviations: AKN, Anakinra; BMI, Body Mass Index; CKN, Canakinumab; DVDIg, Dual Variable Domain Immunoglobulin; EP, Endpoint; HRPQ, Health Related Productivity Questionnaire; IA, intraarticular; IL-1, Interleukin-1; IL-1R, IL-1 receptor; KL, Kellgren Lawrence; LTZ, Lutikizumab; Mab, Monoclonal Antibody; N/D, No data; NPX, Naproxen; NSAIDS, Non-Steroidal Anti-inflammatory Drugs; OA, Osteoarthritis; PBO, Placebo; PGA, Physician Global Assessment; PROs, Patient Reported Outcomes; SC, Subcutaneous; SF-36, Short Form 36; Slow Acting Drugs, Chondroitin Sulfate, Glucosamine, Diacerein, Avocado and Soy extracts.

from Baseline to Day 29 in WOMAC pain. An effect of canakinumab on pain was observed in a subpopulation with elevated Baseline hsCRP levels.³¹

Lutikizumab (Human Dual Variable Domain Immunoglobulin Inhibiting IL-1 α and IL-1 β)

After demonstration of safety and target engagement, evidenced by significant reduction in the serum concentration of hsCRP and MMP-1,⁶⁸ the efficacy of the IL-1 α and - β inhibitor lutikizumab was evaluated in an RCT enrolling 350 patients with radiographic knee OA and MRI/ultrasound synovitis.³⁰ Patients received lutikizumab 25, 100 or 200 mg, or matching placebo SC every 2 weeks for 52 weeks. The co-primary endpoints were the change in WOMAC pain from Baseline to Week 16 and the change in synovitis at Week 26. Lutikizumab showed significant WOMAC pain improvement for the 100 mg dose only at Week 16, and there was no significant change in synovitis for any dose.

What Can We Learn from Cardiovascular Trials?

The value of anti-inflammatory treatments for cardiovascular risk reduction is increasingly recognized.⁶⁹ Since often in cardiovascular drug development large outcome trials are required, other therapeutic areas have started leveraging the wealth of data. Especially for osteoarthritis research, this can be relevant since the target populations are overlapping,⁷⁰ and anti-inflammatory treatments are a cornerstone of OA treatment. In this context, CANTOS evaluated 10,061 patients with prior myocardial infarction and elevated hsCRP, (≥ 2 mg/l) a known risk factor for future cardiac events and a surrogate for systemic low-grade inflammation. Patients were treated with canakinumab 50 mg, 150 mg, 300 mg or placebo subcutaneously every 3 months and followed up to a maximum of 5 years (mean 3.7 years) for the occurrence of a major cardiovascular event. Canakinumab 150 mg significantly reduced the occurrence major cardiovascular events, and all dose levels led to a reduction in hsCRP.³⁷ The large patient number and long follow-up period offered the opportunity to evaluate the effect of IL-1 β inhibition on the incidence of knee joint replacement, analyzed using reporting of intercurrent surgery or adverse events including narratives and case notes.⁴⁰ This post-hoc analysis compared the pooled canakinumab patients to those receiving placebo and revealed incidence rates for total hip and total knee replacement of 0.31 and 0.54 events, respectively, per 100 person-years (HR, 0.58 [CI, 0.42 to 0.80]; $P = 0.001$), with similar benefits seen in the subgroup of 1369 patients who had a medical history of peripheral (i.e., non-spinal) OA (HR, 0.57 [CI, 0.39 to 0.83]).⁴⁰ These OA patients differed from the overall CANTOS population by being older, more likely female, and having a higher BMI and waist circumference than those without OA, suggesting a metabolic syndrome-like phenotype.⁴⁰

Some confirmation of these results comes from another recent post-hoc analysis of a large cardiovascular trial on low-dose colchicine. The low-dose colchicine 2 (LoDoCo 2) trial,³⁸ an investigator initiated randomized controlled trial, enrolled 6528 patients with stable coronary disease for a one-month open label run-in phase, after which 9.4% discontinued for perceived side effects (mostly gastro-intestinal), 6.1% for other reasons, and 5522 patients were randomized to receive daily 0.5 mg of colchicine or placebo. Over the average observation time of 28.55 months, colchicine (on top of standard of care) was shown to reduce the rate of cardiovascular events compared to placebo treatment. In these patients, a post-hoc analysis demonstrated a substantial reduction in total hip and knee joint replacements in the treatment arm (HR, 0.69 [CI, 0.51 to 0.95]). These results were similar in a sensitivity analysis excluding patients with a medical history of gout (HR, 0.68 [CI, 0.49 to 0.94]).³⁹

Although these post-hoc analyses have methodological limitations, the results provided valuable information on a possible role of IL-1 inhibition in the subgroup of patients with metabolic syndrome and merits further evaluation.⁴⁰

How Should We Interpret the Previous Clinical Trials in Light of CANTOS and LoDoCo 2?

The meta-analysis of Yu et al demonstrated a benefit on both pain and function in OA patients; however, this benefit was primarily driven by their included studies on diacerein and autologous preparations.⁶⁷ There is therefore a discordance between the results from the CANTOS and LoDoCo 2 post-hoc analyses^{39,40} and the results of the four knee OA RCTs, included in Yu et al, and discussed above. While none of these RCTs achieved their pre-specified primary endpoints, all of them demonstrated that IL-1 inhibition lowered levels of some biomarkers including hsCRP and IL-6.^{28–31} In all these trials, IL-1 inhibition was safe and well tolerated.

The comparison of clinical trials is generally challenging due to different pharmacodynamics and pharmacokinetic properties of the treatments, routes of administration, and the heterogeneity of patients, especially regarding the presence of systemic or local inflammation (ie, synovitis) which could be the most crucial differentiator for demonstrating benefits of IL-1 inhibition in OA.^{28–31}

While pain is associated with synovitis, and the prevalence of synovitis differs greatly based on the clinical or imaging tools employed,⁷¹ none of those trials met their primary symptomatic endpoint independent of enrichment for synovitis or effusion. On the other hand, the CANTOS and LoDoCo 2 post-hoc analyses, both studies not enriched for OA patients, demonstrated a benefit in terms of joint replacement, an endpoint presumably driven by patient

symptoms.^{39,40} This interesting observation suggests that the efficacy of IL-1 inhibition in OA may depend more on systemic inflammatory status than local joint inflammation.

When trying to understand the discordance, another potential confounder, also raised by Vincent's critical review,³² is the role of crystals. Although the previously cited clinical trials excluded patients with any non-OA arthritis, the prevalence of sub-clinical crystals in OA is known to range between 10% (using imaging) and up to 90% (based on cartilage histology).^{48,72–75} Since IL-1 inhibition has been proven as a valid strategy for the treatment of crystal-induced arthritis,^{76–78} it may be possible that the responses in CANTOS and LoDoCO 2 were biased by un-diagnosed crystal arthropathy, although sensitivity analyses excluding formally diagnosed gout or other types of inflammatory arthritis still demonstrated the substantial reduction in joint replacement.

Baseline pain-levels have an impact on the possibility of detecting a change from baseline,^{79,80} and lower pain levels than seen in recent OA trials may have contributed to the negative findings in some of the above studies. This is supported by the fact that numerically greater improvement in WOMAC pain score at Week 6 in the AMG-108 group was observed in patients with higher pain score at Baseline.²⁹ In addition to slight differences in the pain eligibility criteria in the above studies, pain as an outcome is vulnerable to confounders^{48,80–84} such as analgesic medication that were not controlled in all studies. Finally, the striking magnitude of the placebo effect in two studies, with up to 65%²⁸ and 70.6%³⁰ of patients on placebo achieving the OARSI/OMERACT response criteria,⁸⁵ raises concerns about the methods to control for placebo effects.⁸⁶

Osteoarthritis and the Metabolic Phenotype

Finally, the heterogeneity of the included patients in the previous RCTs may partly explain the inconsistent response to IL-1 inhibition.⁵ Osteoarthritis is comprised of multiple phenotypic subgroups that are assumed to be associated to specific endotypes.^{3,8,11} The “metabolic phenotype” is one of the most extensively studied subgroups.⁸⁷ Knoop et al identified an “obese – weak muscle phenotype” which is associated with worse pain and activity outcomes than the “minimal joint disease”, “strong muscle” and “non-obese and weak muscle” subgroups.⁶ Others have defined the metabolic phenotype as obese with metabolic abnormalities,¹¹ or more specifically by the presence of metabolic syndrome with obesity, hypertension, diabetes and dyslipidemia as well as high levels of biomarkers such as hsCRP or leptin.³ Although as pointed out by Berenbaum et al, the differential impact from metabolic alterations vs obesity is not fully clear yet.¹² Applying unsupervised machine learning algorithms to the Osteoarthritis Initiative database, a “comorbid” cluster of patients, defined by higher BMI and burden of comorbidity showed a higher burden of pain, structural damage, and risk of knee replacement versus the other clusters, and this effect was more pronounced in a cluster with effusion as sign of local inflammation.^{8,88}

Metabolic syndrome (MetS) is a constellation of clinical and biochemical characteristics associated with an increased CVD (cardiovascular disease) risk. Although there is no universally accepted definition, there is consensus on its components: Abdominal obesity, elevated blood pressure, impaired fasting glucose levels, increased triglycerides, and decreased high-density lipoprotein cholesterol levels.⁸⁹ A relationship between CVD risk factors and an augmented prevalence of OA has been observed.⁹⁰ For years, the main hypothesis linking metabolic syndrome and OA was the increase in mechanical loading on weight-bearing joints in obesity. However, increasing work suggests systemic effects beyond biomechanical loading: a cohort study from Norway with a 10-year-long follow-up found an association of obesity with knee and hand OA, but not with hip OA.⁹¹ Similarly, a Japanese study demonstrated an impact of the individual components of MetS on the incidence and progression of OA, as well as an additive effect of individual components.⁹² Since then, several studies demonstrated an increased risk for OA in MetS, independent of weight.⁹³ Additionally, there is growing evidence of an association of metabolic syndrome and chronic low-grade inflammation, with associated dysregulation of CNS and pain tolerance.^{48,94} The link between MetS and OA could be adipokines as comprehensively reviewed by Zhang et al.⁹⁵

Several physio-pathological alterations lead to this chronic low-grade systemic inflammatory state. First, the chronic excess of nutrients present in the MetS induces impairment of the cellular energy and nutrient sensors, inducing an altered mitochondrial function, DNA damage, premature senescence, and reduced organelle autophagy, which leads to chondrocyte apoptosis, and in consequence, increased oxidative stress and inflammation.^{93,96} Second, the expansion of

visceral white adipose tissue induces the expression of adipokines such as leptin and adiponectin, resulting in an enhanced release of IL-1 β , IL-6 and matrix degrading proteins.^{97,98}

A study by Francisco et al found that patients with OA have higher levels of leptin in serum, synovial tissue and cartilage compared to healthy controls.⁹⁷ Furthermore, the knee's infrapatellar fat pad can produce adipokines and exert an amplified paracrine effect.⁹⁹ Third, high fat diets can activate the NLRP3 inflammasome, either directly through the recognition of elevated concentrations of saturated fatty acids by the toll like receptors, or indirectly by inducing the impairment of the gut mucosal barrier, and consequently, an increase of circulating lipopolysaccharides.⁹³ High levels of oxidized cholesterol can induce mitochondrial dysfunction and lead to oxidative stress within the chondrocyte.⁹⁶ Finally, vascular pathology caused by MetS can lead to subchondral ischemia, and thereby induce metabolic stress on the avascular cartilage, and apoptosis of osteocytes and chondrocytes.^{96,100}

Conclusion

OA is a complex disease, with different phenotypes and pathophysiologic pathways involved. Chronic low-grade systemic inflammation associated with metabolic OA phenotype may be a treatable cause of OA pain. Based on the various insights described in this review, IL-1 inhibition remains a potential treatment for OA, but in a selected subset of patients.

Acknowledgments

PGC is supported in part by the United Kingdom National Institute for Health and Care Research Leeds Biomedical Research Centre (NIHR203331). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

The manuscript has initially been developed as part of a fellowship by MB founded by Novartis Biomedical Research. MB, FS, LM and MS have received salaries from Novartis during the work on this manuscript. The funder had no influence on the study design, data interpretation or publication strategy.

Disclosure

Martin Brom is employee and shareholder of Novartis. Franziska Saxer is employee and shareholder of Novartis, she is affiliated to the University Basel and member of the European Union Medical Devices – Expert Panel section Orthopaedics, traumatology, rehabilitation, rheumatology. Linda Mindeholm is consultant to Novartis and Versanis Bio, employee and shareholder of Novartis. In addition, she reports a pending patent WO2019215484A1. Matthias Schieker is employee and shareholder of Novartis, he is owner of LivImplant GmbH. In addition, he reports a pending patent WO2019215484A1. Philip G Conaghan reports consultancies or speakers bureaus for AbbVie, Eli Lilly, FormationBio, Genascense, GlaxoSmithKline, Grunenthal, Janssen, Kolon TissueGene, Levicept, Merck, Moebius, Novartis, Stryker, Takeda and TrialSpark. The authors report no other conflicts of interest in this work.

References

1. Glyn-Jones S, Palmer AJR, Agricola R, et al. Osteoarthritis. *Lancet*. 2015;386(9991):376–387. doi:10.1016/S0140-6736(14)60802-3
2. Steinmetz JD, Culbreth GT, Haile LM, et al. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021. *Lancet Rheumatol*. 2023;5(9):e508–22.

3. Dell'Isola A, Allan R, Smith SL, Marreiros SSP, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. *BMC Musculoskelet Disord*. 2016;17(1):425. doi:10.1186/s12891-016-1286-2
4. Devez LA, Nelson AE, Loeser RF. Phenotypes of osteoarthritis: current state and future implications. *Clin Exp Rheumatol*. 2019;37(Suppl 1):64–72. doi:10.1016/j.joca.2019.06.011
5. Van Spil WE, Kubassova O, Boesen M, Bay-Jensen A-C, Mobasheri A. Osteoarthritis phenotypes and novel therapeutic targets. *Biochem Pharmacol*. 2019;165:41–48. doi:10.1016/j.bcp.2019.02.037
6. Knoop J, van der Leeden M, Thorstensson CA, et al. Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the osteoarthritis initiative. *Arthritis Care Res*. 2011;63(11):1535–1542. doi:10.1002/acr.20571
7. Carlesso LC, Neogi T. Identifying pain susceptibility phenotypes in knee osteoarthritis. *Clin Exp Rheumatol*. 2019;37(Suppl 1):96–99.
8. Demansee D, Saxer F, Lustenberger P, et al. Unsupervised machine-learning algorithms for the identification of clinical phenotypes in the osteoarthritis initiative database. *Semin Arthritis Rheum*. 2023;58:152140.
9. Saxer F, Hollinger A, Bjurström MF, et al. Pain-phenotyping in osteoarthritis: current concepts, evidence, and considerations towards a comprehensive framework for assessment and treatment. *Osteoarthritis Cartil Open*. 2024;6(1):100433. doi:10.1016/j.ocarto.2023.100433
10. Neogi T, Zhang Y. Epidemiology of Osteoarthritis. *Rheum Dis Clin North Am*. 2013;39(1):1–19. doi:10.1016/j.rdc.2012.10.004
11. Devez LA, Loeser RF. Is osteoarthritis one disease or a collection of many? *Rheumatology*. 2018;57(suppl_4):iv34–42. doi:10.1093/rheumatology/kex417
12. Berenbaum F, Wallace JJ, Lieberman DE, Felson DT. Modern-day environmental factors in the pathogenesis of osteoarthritis. *Nat Rev Rheumatol*. 2018;14(11):674–681. doi:10.1038/s41584-018-0073-x
13. Ghouri A, Conaghan PG. Update on novel pharmacological therapies for osteoarthritis. *Ther Adv Musculoskelet Dis*. 2019;11:1759720X1986449. doi:10.1177/1759720X19864492
14. Boraschi D. What is IL-1 for? Functions of interleukin-1 across evolution. *Front Immunol*. 2022;13:872155.
15. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nat Rev Rheumatol*. 2011;7(1):33–42. doi:10.1038/nrrheum.2010.196
16. Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis: a critical review of the state-of-the-art, current prospects, and future challenges. *Bone*. 2016;85:81–90. doi:10.1016/j.bone.2016.01.019
17. Woodell-May JE, Sommerfeld SD. Role of inflammation and the immune system in the progression of osteoarthritis. *J Orthop Res*. 2019;1:jor.24457.
18. Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol*. 2011;23(5):471–478. doi:10.1097/BOR.0b013e328349c2b1
19. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. *Mediators Inflamm*. 2014;2014:1–19. doi:10.1155/2014/561459
20. Jenei-Lanzl Z, Meurer A, Zaucke F. Interleukin-1 β signaling in osteoarthritis – chondrocytes in focus. *Cell Signal*. 2019;53:212–223. doi:10.1016/j.cellsig.2018.10.005
21. Glasson S. In vivo osteoarthritis target validation utilizing genetically-modified mice. *Curr Drug Targets*. 2007;8(2):367–376. doi:10.2174/138945007779940061
22. Pelletier J-P, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. *Arthritis Rheum*. 1997;40(6):1012–1019. doi:10.1002/art.1780400604
23. Caron JP, Fernandes JC, Martel-Pelletier J, et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. *Arthritis Rheum*. 1996;39(9):1535–1544. doi:10.1002/art.1780390914
24. Elsaid KA, Zhang L, Shaman Z, Patel C, Schmidt TA, Jay GD. The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model. *Osteoarthritis Cartilage*. 2015;23(1):114–121. doi:10.1016/j.joca.2014.09.006
25. Elsaid KA, Ubhe A, Shaman Z, D'Souza G. Intra-articular interleukin-1 receptor antagonist (IL1-ra) microspheres for posttraumatic osteoarthritis: in vitro biological activity and in vivo disease modifying effect. *J Exp Orthop*. 2016;3(1):18. doi:10.1186/s40634-016-0054-4
26. D'Lima D, Hermida J, Hashimoto S, Colwell C, Lotz M. Caspase inhibitors reduce severity of cartilage lesions in experimental osteoarthritis. *Arthritis Rheum*. 2006;54(6):1814–1821. doi:10.1002/art.21874
27. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. *J Rheumatol*. 2005;32(7):1317–1323.
28. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*. 2009;61(3):344–352. doi:10.1002/art.24096
29. Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. *Arthritis Res Ther*. 2011;13:R125.
30. Fleischmann RM, Bliddal H, Blanco FJ, et al. A phase ii trial of lutikizumab, an anti-interleukin-1 α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. *Arthritis Rheumatol*. 2019;71(7):1056–1069. doi:10.1002/art.40840
31. Conaghan P, Chevalier X, Mindeholm L, et al. Intra-articular canakinumab (anti-interleukin-1 β) for treatment of symptomatic knee osteoarthritis: a randomized, double-blind, placebo and naproxen-controlled phase ii study. *Arthritis Rheumatol*. 2021;73.
32. Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. *F1000Res*. 2019;8:934. doi:10.12688/f1000research.18831.1
33. Mobasheri A, Saarakkala S, Finnilä M, Karsdal MA, Bay-Jensen A-C, van Spil WE. Recent advances in understanding the phenotypes of osteoarthritis. *F1000Res*. 2019;8:8. doi:10.12688/f1000research.17047.1
34. Angelini F, Wiedera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. *Ann Rheum Dis*. 2022;82(1):81. doi:10.1136/ard-2022-223358
35. Zhuo Q, Yang W, Chen Y, Wang Y. Metabolic syndrome meets osteoarthritis. *Nat Rev Rheumatol*. 2012;9(1):8. doi:10.1038/nrrheum.2012.193
36. Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? *Joint Bone Spine*. 2013;80.
37. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
38. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. *N Engl J Med*. 2020;383(19):1838–1847. doi:10.1056/NEJMoa2021372

39. Heijman MWJ, Fiolet ATL, Mosterd A, et al. Association of low-dose colchicine with incidence of knee and hip replacements. *Ann Intern Med.* 2023;176(6):737–742. doi:10.7326/M23-0289
40. Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1 β inhibition on incident hip and knee replacement. *Ann Intern Med.* 2020;173(7):509–515. doi:10.7326/M20-0527
41. van den Bosch MHJ, van Lent PLEM, van der Kraan PM. *Identifying Effector Molecules, Cells, and Cytokines of Innate Immunity in OA. Osteoarthritis Cartilage.* W.B. Saunders Ltd; 2020:532–543.
42. Chow YY, Chin KY. The role of inflammation in the pathogenesis of osteoarthritis. *Mediators Inflamm.* 2020;2020:1–19. [Hindawi Limited]. doi:10.1155/2020/8293921
43. Choi MC, Jo J, Park J, Kang HK, Park Y. NF-B signaling pathways in osteoarthritic cartilage destruction. *Cells.* 2019;8(7):734. doi:10.3390/cells8070734
44. Attur MG, Dave M, Cipolletta C, et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor: potential for pharmacological intervention. *J Biol Chem.* 2000;275(51):40307–40315. doi:10.1074/jbc.M002721200
45. Budhiparama NC, Lumban-Gaol I, Sudoyo H, Magetsari R, Wibawa T. Interleukin-1 genetic polymorphisms in knee osteoarthritis: What do we know? A meta-analysis and systematic review. *J Orthop Surg.* 2022;30(1):230949902210766. doi:10.1177/23094990221076652
46. Lee AS, Ellman MB, Yan D, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. *Gene.* 2013;527(2):440–447. doi:10.1016/j.gene.2013.05.069
47. Perrot S. Osteoarthritis pain. *Best Pract Res Clin Rheumatol.* 2015;29(1):90–97. doi:10.1016/j.berh.2015.04.017
48. Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. *Nat Rev Rheumatol.* 2019;15(6):355–363. doi:10.1038/s41584-019-0221-y
49. Binshtok AM, Wang H, Zimmermann K, et al. Nociceptors are interleukin-1 β sensors. *J Neurosci.* 2008;28(52):14062–14073. doi:10.1523/JNEUROSCI.3795-08.2008
50. Salaffi F, Ciapetti A, Carotti M. The sources of pain in osteoarthritis: a pathophysiological review. *Reumatismo.* 2014;66(1):57. doi:10.4081/reumatismo.2014.766
51. Berenbaum F, Meng Q-J. The brain–joint axis in osteoarthritis: nerves, circadian clocks and beyond. *Nat Rev Rheumatol.* 2016;12(9):508–516. doi:10.1038/nrrheum.2016.93
52. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1 β , interleukin-6, and tumor necrosis factor- α in regulating synaptic and neuronal activity in the superficial spinal cord. *J Neurosci.* 2008;28(20):5189–5194. doi:10.1523/JNEUROSCI.3338-07.2008
53. Gruber-Schoffnegger D, Drdla-Schutting R, Hönigsperger C, Wunderbaldinger G, Gassner M, Sandkühler J. Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord Lamina I by TNF- α and IL-1 β is mediated by glial cells. *J Neurosci.* 2013;33(15):6540–6551. doi:10.1523/JNEUROSCI.5087-12.2013
54. Taves S, Berta T, Chen G, Ji RR. *Microglia and Spinal Cord Synaptic Plasticity in Persistent Pain.* Neural Plast. Hindawi Publishing Corporation; 2013.
55. Del Rey A, Yau HJ, Randolph A, et al. Chronic neuropathic pain-like behavior correlates with IL-1 β expression and disrupts cytokine interactions in the hippocampus. *Pain.* 2011;152(12):2827–2835. doi:10.1016/j.pain.2011.09.013
56. Gui WS, Wei X, Mai CL, et al. Interleukin-1 β overproduction is a common cause for neuropathic pain, memory deficit, and depression following peripheral nerve injury in rodents. *Mol Pain.* 2016;12:1744806916646784.
57. Fülöp B, Hunyady Á, Bencze N, et al. IL-1 mediates chronic stress-induced hyperalgesia accompanied by microglia and astroglia morphological changes in pain-related brain regions in mice. *Int J Mol Sci.* 2023;25(1):24. doi:10.3390/ijms25010024
58. Rossi S, Sacchetti L, Napolitano F, et al. Interleukin-1 β causes anxiety by interacting with the endocannabinoid system. *J Neurosci.* 2012;32(40):13896–13905. doi:10.1523/JNEUROSCI.1515-12.2012
59. Burston JJ, Valdes AM, Woodhams SG, et al. The impact of anxiety on chronic musculoskeletal pain and the role of astrocyte activation. *Pain.* 2019;160(3):658–669. doi:10.1097/j.pain.0000000000001445
60. Gómez Penedo JM, Rubel JA, Blättler L, et al. The complex interplay of pain, depression, and anxiety symptoms in patients with chronic pain: a network approach. *Clin J Pain.* 2020;36(4):249–259. doi:10.1097/AJP.0000000000000797
61. Attur M, Belitskaya-Lévy I, Oh C, et al. Increased interleukin-1 β gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. *Arthritis Rheum.* 2011;63(7):1908–1917. doi:10.1002/art.30360
62. Glasson SS, Blanchet TJ, Morris EA. Less severe OA is observed in the IL-1 beta KO and more severe OA is observed in the MMP-9 and MK2 KO mice in a surgical model of OA. *Trans Orthop Res Soc.* 2005;251.
63. Uebelhoer M, Lambert C, Grisart J, Guse K, Plutizki S, Henrotin Y. Interleukins, growth factors, and transcription factors are key targets for gene therapy in osteoarthritis: a scoping review. *Front Med Lausanne.* 2023;10. <https://www.frontiersin.org/articles/10.3389/fmed.2023.1148623/full>.
64. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. Gene deletion of either interleukin-1B, interleukin-1B-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial. *Arthritis Rheum.* 2003;48(12):3452–3463. doi:10.1002/art.11355
65. van Dalen SCM, Blom AB, Sløetjes AW, et al. Interleukin-1 is not involved in synovial inflammation and cartilage destruction in collagenase-induced osteoarthritis. *Osteoarthritis Cartilage.* 2017;25(3):385–396. doi:10.1016/j.joca.2016.09.009
66. Del Rey A, Apkarian AV, Martina M, Besedovsky HO. Chronic neuropathic pain-like behavior and brain-borne IL-1 β . *Ann N Y Acad Sci.* 2012;1262(1):101–107. doi:10.1111/j.1749-6632.2012.06621.x
67. Yu L, Luo R, Qin G, Zhang Q, Liang W. Efficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. *J Orthop Surg Res.* 2023;18(1):18. doi:10.1186/s13018-023-03503-3
68. Kosloski MP, Goss S, Wang SX, et al. Pharmacokinetics and tolerability of a dual variable domain immunoglobulin ABT-981 against IL-1 α and IL-1 β in healthy subjects and patients with osteoarthritis of the knee. *J Clin Pharmacol.* 2016;56(12):1582–1590. doi:10.1002/jcph.764
69. Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation. *Agin Cardiovasc Dis J Am Coll Cardiol.* 2022;79(8):837–847. doi:10.1016/j.jacc.2021.12.017

70. Bierma-Zeinstra SMA, Hoesen TA, Waarsing JH. Is having OA an independent risk factor for cardiovascular events? *Osteoarthritis Cartilage*. **2017**;25(7):997–999. doi:10.1016/j.joca.2017.03.005
71. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. *Arthritis Res Ther*. **2017**;19(1):18. doi:10.1186/s13075-017-1229-9
72. Hügler T, Geurts J. What drives osteoarthritis?—synovial versus subchondral bone pathology. *Rheumatology*. **2016**;56(kew 389).
73. Frallonardo P, Ramonda R, Peruzzo L, et al. Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. *Clin Rheumatol*. **2018**;37(10):2847–2853. doi:10.1007/s10067-018-4166-3
74. Ibad HA, Kwee RM, Ghotbi E, Roemer FW, Guermazi A, Demehri S. Radiographically detectable intra-articular mineralization: predictor of knee osteoarthritis outcomes or only an indicator of aging? A brief report from the osteoarthritis initiative. *Osteoarthritis Cartil Open*. **2023**;5(2):100348. doi:10.1016/j.ocarto.2023.100348
75. Liew JW, Jarraya M, Guermazi A, et al. Relation of intra-articular mineralization to knee pain in knee osteoarthritis: a longitudinal analysis in the most study. *Arthritis Rheumatol*. **2023**;75(12):2161–2168. doi:10.1002/art.42649
76. Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of interleukin-1 β blockade with incident gout and serum uric acid levels. *Ann Intern Med*. **2018**;169(8):535. doi:10.7326/M18-1167
77. Dumusc A, So A. Interleukin-1 as a therapeutic target in gout. *Curr Opin Rheumatol*. **2015**;27(2):156–163. doi:10.1097/BOR.0000000000000143
78. Thomas M, Forien M, Palazzo E, Dieudé P, Ottaviani S. Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases. *Clin Rheumatol*. **2019**;38(2):425–430. doi:10.1007/s10067-018-4272-2
79. Wenham C, McDermott M, Conaghan P. Biological therapies in osteoarthritis. *Curr Pharm Des*. **2015**;21(17):2206–2215. doi:10.2174/1381612821666150310144940
80. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. *Pain*. **2012**;153(6):1148–1158. doi:10.1016/j.pain.2012.03.003
81. Arendt-Nielsen L. Pain sensitisation in osteoarthritis. *Clin Exp Rheumatol*. **2017**;35(Suppl 107):68–74.
82. Edwards RR, Dworkin RH, Turk DC, et al. *Patient Phenotyping in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations*. Pain. Lippincott Williams and Wilkins; **2016**:1851–1871.
83. Petrini L, Arendt-Nielsen L. Understanding pain catastrophizing: putting pieces together. *Front Psychol Frontiers Media S A*. **2020**;11. doi:10.3389/fpsyg.2020.603420
84. Boersma K, Linton SJ. How does persistent pain develop? An analysis of the relationship between psychological variables, pain and function across stages of chronicity. *Behav Res Therap*. **2005**;43(1):43. doi:10.1016/j.brat.2003.11.004
85. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthritis Cartilage*. **2004**;12(5):389–399. doi:10.1016/j.joca.2004.02.001
86. Kessels R, Mozer R, Bloemers J. Methods for assessing and controlling placebo effects. *Stat Methods Med Res*. **2019**;28:1141–1156.
87. Mobasheri A, Rayman MP, Gualillo O, Sellam J, van der Kraan P, Fearon U. The role of metabolism in the pathogenesis of osteoarthritis. *Nat Rev Rheumatol*. **2017**;13(5):302–311. doi:10.1038/nrrheum.2017.50
88. Saxer F, Demanase D, Brett A, et al. Prognostic value of B-score for predicting joint replacement in the context of osteoarthritis phenotypes: data from the osteoarthritis initiative. *Osteoarthritis Cartil Open*. **2024**;6(2):100458. doi:10.1016/j.ocarto.2024.100458
89. Oda E. Historical perspectives of the metabolic syndrome. *Clin Dermatol*. **2018**;36(1):3–8. doi:10.1016/j.clindermatol.2017.09.002
90. Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the third national health and nutrition examination survey. *Am J Manag Care*. **2002**;8(15 Suppl):S383–91.
91. Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis in knee, hip and/or hand: an epidemiological study in the general population with 10 years follow-up. *BMC Musculoskelet Disord*. **2008**;9(1):132. doi:10.1186/1471-2474-9-132
92. Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. *Osteoarthritis Cartilage*. **2012**;20:1217–1226.
93. Berenbaum F, Griffin TM, Liu-Bryan R. Review: metabolic regulation of inflammation in osteoarthritis. *Arthritis Rheumatol*. **2017**;69(1):9–21. doi:10.1002/art.39842
94. Morris JL, Letson HL, Gillman R, et al. The CNS theory of osteoarthritis: opportunities beyond the joint. *Semin Arthritis Rheum*. **2019**;000:1–6.
95. Zhang Q, Zhao Y, Li L, et al. Metabolism-related adipokines and metabolic diseases: their role in osteoarthritis. *J Inflamm Res*. **2025**;18:1207–1233. doi:10.2147/JIR.S499835
96. Bortoluzzi A, Furini F, Scirè CA. Osteoarthritis and its management - epidemiology, nutritional aspects and environmental factors. *Autoimmun Rev*. **2018**;17(11):1097–1104. doi:10.1016/j.autrev.2018.06.002
97. Francisco V, Ruiz-Fernández C, Pino J, et al. Adipokines: linking metabolic syndrome, the immune system, and arthritic diseases. *Biochem Pharmacol*. **2019**;165:196–206. doi:10.1016/j.bcp.2019.03.030
98. Tu C, He J, Wu B, Wang W, Li Z. An extensive review regarding the adipokines in the pathogenesis and progression of osteoarthritis. *Cytokine*. **2019**;113:1–12. doi:10.1016/j.cyto.2018.06.019
99. Eymard F, Chevalier X. Inflammation of the infrapatellar fat pad. *Joint Bone Spine*. **2016**;83(4):389–393. doi:10.1016/j.jbspin.2016.02.016
100. Chadha R. Revealed aspect of metabolic osteoarthritis. *J Orthop*. **2016**;13(4):347–351. doi:10.1016/j.jor.2016.06.029

Diabetes, Metabolic Syndrome and Obesity**Dovepress**

Taylor & Francis Group

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>